Akt-Dependent Cytokine Production in Mast Cells by Kitaura, Jiro et al.
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/2000/09/729/11 $5.00
Volume 192, Number 5, September 4, 2000 729–739
http://www.jem.org/cgi/content/full/192/5/729
 
729
 
Akt-dependent Cytokine Production in Mast Cells
 
By Jiro Kitaura,
 
*
 
 Koichi Asai,
 
*
 
 Mari Maeda-Yamamoto,
 
‡
 
Yuko Kawakami,
 
*
 
 Ushio Kikkawa,
 
§
 
 and Toshiaki Kawakami
 
*
 
From the 
 
*
 
Division of Allergy, La Jolla Institute for Allergy and Immunology, San Diego, California 
 
92121; the 
 
‡
 
National Research Institute of Vegetables, Ornamental Plants, and Tea, Shizuoka 
428-8501, Japan; and the 
 
§
 
Biosignal Research Center, Kobe University, Kobe 657-8501, Japan
 
Abstract
 
Cross-linking of Fc
 
e
 
RI induces the activation of three protein tyrosine kinases, Lyn, Syk, and
Bruton’s tyrosine kinase (Btk), leading to the secretion of a panel of proinflammatory mediators
from mast cells. This study showed phosphorylation at Ser-473 and enzymatic activation of
Akt/protein kinase B, the crucial survival kinase, upon Fc
 
e
 
RI stimulation in mouse mast cells.
Phosphorylation of Akt is regulated positively by Btk and Syk and negatively by Lyn. Akt in
turn can regulate positively the transcriptional activity of interleukin (IL)-2 and tumor necrosis
factor (TNF)-
 
a
 
 promoters. Transcription from the nuclear factor 
 
k
 
B (NF-
 
k
 
B), nuclear factor
of activated T cells (NF-AT), and activator protein 1 (AP-1) sites within these promoters is un-
der the control of Akt activity. Accordingly, the signaling pathway involving I
 
k
 
B-
 
a
 
, a cyto-
plasmic protein that binds NF-
 
k
 
B and inhibits its nuclear translocation, appears to be regulated
by Akt in mast cells. Catalytic activity of glycogen synthase kinase (GSK)-3
 
b
 
, a serine/threo-
nine kinase that phosphorylates NF-AT and promotes its nuclear export, seems to be inhibited
by Akt. Importantly, Akt regulates the production and secretion of IL-2 and TNF-
 
a
 
 in Fc
 
e
 
RI-
stimulated mast cells. Altogether, these results revealed a novel function of Akt in transcrip-
tional activation of cytokine genes via NF-
 
k
 
B, NF-AT, and AP-1 that contributes to the pro-
duction of cytokines.
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Introduction
 
Akt/protein kinase B (referred to as Akt hereafter), origi-
nally identified by its similarity to protein kinases A and C
(1, 2) and also found in a rodent oncogenic retroviral ge-
nome (3), is a pleiotropic protein serine/threonine kinase
 
composed of an NH
 
2
 
-terminal pleckstrin homology (PH)
 
1
 
domain and a COOH-terminal catalytic domain. Akt is ac-
tivated by numerous stimuli and is implicated in a variety
of cellular functions, such as survival, metabolism, tran-
scription, and translation (for reviews, see references 4–9).
In response to growth factors that activate phosphatidyl-
inositol 3-kinase (PI3K), the membrane-bound lipid phos-
phatidylinositol 3,4,5-trisphosphate (PIP3) is synthesized
and recruits 3-phosphoinositide–dependent kinase (PDK)1
(10–12) by binding to its PH domain. PIP3 and phosphati-
dylinositol 3,4-bisphosphate recruit Akt to the plasma
membrane by interacting with the PH domain of Akt (13,
14). PDK1 phosphorylates Thr-308 of Akt and PDK2, a
putative kinase yet to be cloned (10), phosphorylates Ser-
473 of Akt. Akt phosphorylated at both sites becomes ac-
tive and phosphorylates target proteins. Other stimuli such
as heat shock, hyperosmolarity, okadaic acid, and cAMP
activate Akt in a PI3K-independent manner (15–18).
Mast cells are crucial effector cells for IgE-dependent im-
mediate hypersensitivity (19). Contact with multivalent an-
tigen activates IgE-bound mast cells, culminating in de-
granulation releasing vasoactive amines and secretion of
lipid mediators, various proteases, and various cytokines.
This high-affinity IgE receptor (Fc
 
e
 
RI)-dependent activa-
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 AP-1, activator protein 1; BMMC,
bone marrow–derived mast cell; Btk, Bruton’s tyrosine kinase; DN, dom-
inant negative; ERK, extracellular signal–regulated kinase; GSK, glyco-
gen synthase kinase; HA, hemagglutinin; HSA, human serum albumin;
IKK, I
 
k
 
B kinase; ITAM, immunoreceptor tyrosine-based activation mo-
tif; JNK, c-Jun NH
 
2
 
-terminal kinase; MAPK, mitogen-activated protein
kinase; MEKK, MEK kinase; NF-
 
k
 
B, nuclear factor 
 
k
 
B; PDK, 3-phos-
phoinositide–dependent kinase; PH, pleckstrin homology; PI3K, phos-
phatidylinositol 3-kinase; PLC, phospholipase C; PTK, protein tyrosine
kinase; RBL, rat basophilic leukemia; SCF, stem cell factor; SH, Src ho-
mology; wt, wild-type. 
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tion has been a focus of intense study. Fc
 
e
 
RI consists of
four subunits, i.e., one IgE-binding 
 
a
 
 subunit, one 
 
b
 
, and
two S-S–bonded 
 
g
 
 subunits (20). According to the broadly
accepted hypothesis (21–23), Fc
 
e
 
RI cross-linking elicits the
activation of 
 
b
 
 subunit–bound Lyn, a Src family protein ty-
rosine kinase (PTK). Active Lyn phosphorylates tyrosine
residues in the immunoreceptor tyrosine-based activation
motifs (ITAMs [24]) within both 
 
b
 
 and 
 
g
 
 subunits. Phos-
phorylated 
 
b
 
-ITAM and phosphorylated 
 
g
 
-ITAM recruit
Lyn and Syk, respectively, via Src homology (SH)2 do-
main–phosphotyrosine interactions. Lyn has an SH2 do-
main, and Syk has two tandem SH2 domains. Activation of
these PTKs ensues by phosphorylation of tyrosine residues
in the activation loop and conformational changes induced
by binding to phosphorylated ITAMs (25–27). Active Lyn
and Syk phosphorylate numerous target proteins, including
phospholipase C (PLC)-
 
g
 
. Phosphorylation and activation
of PLC-
 
g
 
 requires the concerted action of Syk and another
PTK, Bruton’s tyrosine kinase (Btk [28, 29]). Hydrolysis of
phosphatidylinositol 4,5-bisphosphate by PLC generates
two second messengers, inositol 1,4,5-trisphosphate (IP3)
and diacylglycerol. IP3 recruits Ca
 
2
 
1
 
 from cellular storage
sites, and diacylglycerol activates protein kinase C isoforms
(30, 31). Optimal degranulation requires Ca
 
2
 
1
 
 and protein
kinase C (32).
Downstream of the above early activation events, three
major subfamilies of mitogen-activated protein kinases
(MAPKs), i.e., extracellular signal–regulated kinases (ERKs
[33–36]), c-Jun NH
 
2
 
-terminal kinases (JNKs [37, 38]), and
p38 (39), are activated upon Fc
 
e
 
RI cross-linking. In mast
cells, ERK1 and ERK2 are under the control of Syk and
Ras (39), whereas JNK1 and JNK2 are regulated in a Lyn/
Syk/Btk-dependent manner (38, 40). p38 is also regulated
by Btk (38). MAPKs regulate various transcription factors.
For example, JNK phosphorylates and activates c-Jun,
which dimerizes with Fos and binds to activator protein 1
(AP-1) sites in various gene promoters, including those for
cytokine genes (for a review, see reference 41). Promoters
in cytokine genes such as those coding for IL-2 and TNF-
 
a
 
contain other cis-elements that are bound by important
transcription factors such as nuclear factor of activated T
cells (NF-AT) and nuclear factor 
 
k
 
B (NF-
 
k
 
B [42–46]).
Nuclear location and activity of NF-AT are controlled by
Ca
 
2
 
1
 
-dependent phosphatase calcineurin and Ras (for a re-
view, see reference 47). NF-
 
k
 
B is activated by a variety of
inflammatory stimuli via the recently defined pathways
that involve NF-
 
k
 
B–inducing kinase (NIK [48, 49]), Cot/
Tpl-2 (50), and MEK kinase (MEKK)1, -2, and -3 (51–
54). These MAPK kinase kinases can activate the I
 
k
 
B ki-
nase (IKK) complex of serine/threonine kinases and a co-
factor (55–59). IKK in turn phosphorylates and induces the
degradation of I
 
k
 
B (an NF-
 
k
 
B–sequestering protein fam-
ily; for a review, see reference 60). However, signaling
pathways leading to the activation of NF-
 
k
 
B in mast cells
are little known.
In this study, we found that Akt is activated upon cross-
linking of Fc
 
e
 
RI in mast cells. Using primary cultured mast
cells and mast cell lines deficient in PTK critical for mast
 
cell activation, we investigated the requirements for Akt
activation. Downstream of Akt activation, the signaling
pathways to transcriptional activation of cytokine genes
were analyzed. Importantly, we revealed that Akt is criti-
cally involved in cytokine production induced by Fc
 
e
 
RI
stimulation.
 
Materials and Methods
 
Reagents.
 
Culture media and FCS were purchased from Life
Technologies. Sources of commercial antibodies are as follows:
anti-Btk (M-138), anti-Lyn (44), anti-Syk (C-20), anti–PLC-
 
g
 
2
(Q-20), anti-JNK1 (C-17), and anti-ERK1 (C-16) were from
Santa Cruz Biotechnology, Inc.; antiphosphotyrosine mAb 4G10,
anti–PLC-
 
g
 
1 mAbs, and anti-Akt antibody were from Upstate
Biotechnology; antiphospho-Akt (Ser473), antiphospho-Akt
(Thr308), antiphospho–I
 
k
 
B-
 
a
 
 (Ser32), and antiphospho-MAPK
were from New England Biolabs, Inc.; and antiphospho–glyco-
gen synthase kinase (GSK)-3
 
b
 
 (Ser9) and anti–GSK-3
 
a
 
/
 
b
 
 were
from Biosource International. A PTK inhibitor (genistein), PI3K
inhibitors (wortmannin and LY294002), and Pansorbin were
purchased from Calbiochem. Other chemicals of the highest
grade available were obtained from Sigma-Aldrich or Fisher Sci-
entific, unless otherwise mentioned.
 
Cells. btk
 
2
 
/
 
2 
 
and 
 
lyn
 
2
 
/
 
2
 
 mice, each on a mixed C57BL/6 
 
3
 
129/Sv genetic background, were mated to generate 
 
btk
 
1
 
/
 
2
 
lyn
 
1
 
/
 
2
 
F1 progeny. These F1 mice were mated to obtain wild-type (wt),
 
btk
 
2
 
/
 
2
 
, 
 
lyn
 
2
 
/
 
2
 
, and 
 
btk
 
2
 
/
 
2
 
lyn
 
2
 
/
 
2
 
 mice (61). Genotyping was done
by Southern blotting or PCR analysis of mouse tail–derived
DNAs. Mast cells were cultured as described previously (62). In
brief, bone marrow cells derived from femur of the 6–10-wk-old
mice were cultured in RPMI 1640 medium supplemented with
10% FCS, 100 
 
m
 
M nonessential amino acids, 50 
 
m
 
M 2-ME, and
8% conditioned medium of IL-3 gene-transfected cells (bone
marrow–derived mast cell [BMMC] medium). More than 95% of
the Trypan blue–excluding viable cells were mast cells after 4 wk
of culture. No discernible differences in morphology and expres-
sion of early signaling proteins, including Fc
 
e
 
RI
 
b
 
, Fc
 
e
 
RI
 
g
 
, Syk,
Grb2, PLC-
 
g
 
2, c-Cbl, and Shc were detected among these four
types of BMMCs (data not shown). Surface expression of Fc
 
e
 
RI
at similar levels was confirmed by flow cytometry using a FACS-
Calibur™ apparatus and CELLQuest™ software (Becton Dickin-
son). In acute (
 
#
 
60 min) Fc
 
e
 
RI stimulation experiments, BMMCs
were sensitized by an overnight incubation with 0.5–1 
 
m
 
g/ml
antidinitrophenyl (DNP) IgE mAb, washed once in Tyrode
buffer (112 mM NaCl, 2.7 mM KCl, 0.4 mM NaH
 
2
 
PO
 
4
 
, 1.6
mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 10 mM Hepes [pH 7.5], 0.05% gela-
tin, 0.1% glucose), resuspended in Tyrode buffer to 2 
 
3
 
 10
 
7
 
 cells/
ml, and stimulated by polyvalent antigen, 100 ng/ml DNP con-
jugates of human serum albumin (DNP-HSA) for the indicated
time intervals.
Rat basophilic leukemia (RBL)-2H3 is a rat mast cell line used
extensively for studies on Fc
 
e
 
RI signal transduction. A Syk-defi-
cient RBL-2H3 variant and its 
 
syk
 
 cDNA-transfected cell line
(63) were provided by Dr. Reuben P. Siraganian (National Insti-
tutes of Health, Bethesda, MD).
 
Retroviral Transfection.
 
Hemagglutinin (HA)-tagged Akt cDNAs
were recloned into the EcoRI and XhoI sites of the retroviral
vector pMX-puro (38). These plasmids were transfected into
BOSC-23 packaging cells with Lipofectamine (Life Technolo-
gies) to generate recombinant retroviruses. BMMCs were in-
fected with the retroviruses in the presence of 10 
 
m
 
g/ml poly- 
731
 
Kitaura et al.
 
brene, and drug selection was started 48 h after infection. Mass
populations of puromycin-resistant cells were grown and then
cultured in the absence of selection drug for 48 h before Fc
 
e
 
RI
stimulation.
 
Measurements of Secreted Cytokines.
 
For cytokine measure-
ments, mast cells were stimulated in BMMC medium instead of
Tyrode buffer. TNF-
 
a
 
 and IL-2 secreted into the culture medium
for 20 h were measured by ELISA kits (Endogen).
 
Immunoblotting and Immunoprecipitation.
 
Cells were lysed in
ice-cold 1% NP-40–containing lysis buffer (20 mM Tris-HCl
[pH 8.0], 0.15 M NaCl, 1 mM EDTA, 1 mM sodium orthovan-
adate, 1 mM phenylmethylsulfonyl fluoride, 10 
 
m
 
g/ml aprotinin,
10 
 
mg/ml leupeptin, 25 mM  p-nitrophenyl  p9-guanidinoben-
zoate, 1 mM pepstatin, and 0.1% sodium azide) immediately after
stimulation. Lysates were centrifuged in an Eppendorf microcen-
trifuge at 48C for 10 min. Protein concentrations were measured
using DC protein assay reagents (Bio-Rad Laboratories). Cleared
lysates were either directly analyzed by SDS-PAGE or immuno-
precipitated before SDS-PAGE analysis. For immunoprecipita-
tion, lysates were incubated on ice with an appropriate antibody
for 2–4 h, and immune complexes were recovered by brief cen-
trifugation after another 30-min incubation with Pansorbin for
rabbit polyclonal antibodies or anti–mouse immunoglobulin-
conjugated agarose (Sigma-Aldrich) for mouse mAbs. Immune
complexes were washed in lysis buffer four times before SDS-
PAGE analysis. Proteins separated by SDS-PAGE were electro-
phoretically transferred to polyvinylidene difluoride (PVDF)
membranes (NEN Life Science Products). Membranes were
blocked, then incubated consecutively with primary antibody
and horseradish peroxidase–conjugated secondary antibody, and
immunoreactive proteins were visualized by enhanced chemilu-
minescence reagents (NEN Life Science Products).
Immune Complex Kinase Assays. Akt kinase assays were per-
formed as described previously (64). In brief, cells were lysed on
ice for 15 min in ice-cold 1% NP-40–containing lysis buffer.
Cleared lysates were incubated with anti-Akt (Upstate Biotech-
nology) and protein G agarose (Santa Cruz Biotechnology, Inc.).
Akt immunoprecipitates were washed four times in the lysis
buffer and once with kinase buffer (20 mM 3-[N-morpholine]
propanesulfonic acid [MOPS], pH 7.2, 25 mM sodium b-glyc-
erophosphate, 1 mM dithiothreitol [DTT], 15 mM MgCl2, 5
mM EGTA, and 1 mM Na orthovanadate). Washed immuno-
precipitates were incubated at 308C for 15 min with kinase
buffer supplemented with 1 mg/ml microcystin (Sigma-Aldrich)
and 2.5 mg histone H2B in the presence of [g-32P]ATP. Reac-
tions were terminated with SDS sample buffer and analyzed by
SDS-PAGE, followed by electroblotting onto PVDF membranes
and autoradiography. ERK and JNK kinase assays were done as
described previously (38). Cells were lysed in 1% NP-40–con-
taining lysis buffer. Cleared lysates were immunoprecipiated with
anti-ERK1 (Zymed Laboratories) or JNK1 with an aid of Pan-
sorbin. Immunoprecipitates were washed three times with 1%
NP-40–containing lysis buffer and once with kinase buffer (20
mM Hepes [pH 7.4], 10 mM MgCl2, 22 mM DTT, 20 mM
b-glycerophosphate, and 50 mM Na3VO4). Immune complexes
were incubated with 3 mg myelin basic protein (for ERK assays)
or 3 mg of glutathione S-transferase (GST)-c-Jun(1–79) (for JNK
assays) in the kinase buffer in the presence of [g-32P]ATP. Reac-
tions were analyzed as above.
Transcriptional Activity Assay with Luciferase Reporter Con-
structs. Luciferase reporter constructs, the mouse IL-2 (2321)/
luc, the human TNF-a (2200)/luc, NF-kB/luc, AP-1/luc, and
NF-AT/luc were described previously (65). 1–1.5 3 107 mast
cells were transfected with 5–10 mg reporter plasmids singly or
together with 2 or 20 mg each of empty vector, wt Akt (66),
E40K Akt, K179M Akt (provided by Dr. P. Blume-Jensen, Salk
Institute, La Jolla, CA; reference 67), AAA Akt vectors (provided
by Dr. J.R. Woodgett, Ontario Cancer Institute, Toronto, Can-
ada; reference 68), dominant negative (DN) IkB-a (IkBaM; pro-
vided by Dr. Van Antwerp, Salk Institute, La Jolla, CA; reference
69), DN IKKa (provided by A. Altman, La Jolla Institute for Al-
lergy and Immunology, San Diego, CA; reference 70), or DN
GSK-3b (K85M/K86I mutant; provided by Dr. J.R. Woodgett
and Dr. G.R. Crabtree [Stanford University, Palo Alto, CA]; ref-
erence 71) by electroporation at 400 V, 950 mF using a Gene
Pulser II apparatus (Bio-Rad Laboratories). Both K179M Akt and
AAA Akt with K179A/T308A/S473A substitutions are DN mu-
tants. Transfected cells were sensitized overnight with anti-DNP
IgE and left unstimulated or stimulated with 30 ng/ml DNP-
HSA for 8 h before cell harvest. Cells were lysed in 0.2% Triton
X-100 in 100 mM potassium phosphate buffer (pH 7.8)/1 mM
DTT. Luminescence of cleared lysates was measured after addi-
tion of luciferin solution using a model Monolight 2010 lumi-
nometer (Analytical Luminescence Laboratory).
Results
Akt Activation by FceRI Cross-Linking in Mast Cells. Be-
cause Akt is activated by numerous stimuli, we investigated
whether FceRI cross-linking induces Akt activation. In situ
Akt activity was monitored before and after cell stimulation
by immunoblotting with a phosphospecific antibody to the
phosphorylated Ser-473 of Akt. Ser-473 phosphorylation is
Figure 1. Activation of Akt in mast cells by growth factor or FceRI
stimulation. (A) BMMCs sensitized overnight with anti-DNP IgE were
stimulated with 100 ng/ml DNP-HSA for the indicated amounts of time.
Cells were lysed, and lysates were analyzed by SDS-PAGE followed by
immunoblotting with antiphospho-Akt antibody that specifically recog-
nizes the phosphorylated Ser-473 residue and its flanking sequence. The
same blot was reprobed with anti-Akt antibody (left). Shown is the result
representative of at least five independent experiments. Cell lysates were
immunoprecipitated with anti-Akt, and immune complexes were sub-
jected to kinase assays using histone H2B as an exogenous substrate
(right). The kinase result is representative of three similar experiments.
Stim., stimulation. (B) IgE-sensitized BMMCs were pretreated with the
indicated concentrations of genistein, wortmannin, or LY294002 for 15
min before antigen (100 ng/ml DNP-HSA) stimulation (Stim.) for 10
min. Cell lysates were analyzed for Ser-473 phosphorylation as above.732 Akt Activation in Mast Cells
crucial for Akt activation. Antigen treatment of IgE-primed
BMMCs caused a remarkable phosphorylation of Ser-473
at its peak z3–10 min after antigen stimulation (Fig. 1 A,
left). Enzymatic activation of Akt in a time course similar
to that of Ser-473 phosphorylation was shown in in vitro
kinase assays on anti-Akt immunoprecipitates using histone
H2B as an exogenous substrate (Fig. 1 A, right). Depen-
dence of FceRI-induced Akt activation on PTK was re-
vealed by pretreatment of BMMCs with genistein, similar
to BCR-induced Akt activation (64, 72, 73). PI3K inhibi-
tors wortmannin and LY294002 also blocked Akt activa-
tion very efficiently, confirming the PI3K dependence of
Akt activation (Fig. 1 B). These results are consistent with
PI3K activation induced by the engagement of FceRI and
other related receptors that induces activation of several
PTKs as well (74–77).
Hyperphosphorylation of Akt in Lyn-deficient Cells and Re-
duced Akt Phosphorylation in Btk- and Syk-deficient Cells.
PTK dependence of Akt phosphorylation induced by
FceRI cross-linking was further studied using BMMCs de-
rived from lyn2/2 and btk2/2 mice and a Syk-deficient
variant of RBL-2H3 rat mast cells. Strikingly, lyn2/2 cells
showed a severalfold more robust and prolonged Akt Ser-
473 phosphorylation than wt cells (Fig. 2 A). In contrast,
btk2/2 mast cells exhibited a reduced phosphorylation of
Akt compared to wt cells (Fig. 2 B). btk2/2lyn2/2 double-
mutant cells showed a prolonged, but not stronger, phos-
phorylation compared with wt cells (Fig. 2 A), indicating
that the enhanced Akt phosphorylation in lyn2/2 cells is
dependent on Btk. On the other hand, wt RBL-2H3 cells
exhibited high basal levels of Akt Ser-473 phosphorylation
and further induction upon FceRI stimulation (Fig. 2 C),
consistent with the presence of active mutations of c-Kit,
the receptor for stem cell factor (SCF), in this and other
mast cell lines (78). But basal and induced levels of Akt
phosphorylation were significantly reduced in Syk-defi-
cient RBL-2H3 cells and enhanced in Syk-deficient cells
transfected with wt syk cDNA (Fig. 2 C). These results
demonstrate that Akt activity is regulated positively by Syk
and Btk and negatively by Lyn in mast cells.
Regulation of IL-2 and TNF-a Promoters by Akt. One of
the cardinal features of FceRI-induced mast cell activation
is the production and secretion of various cytokines in-
cluding IL-2 and TNF-a, at least partly through the tran-
scriptional activation of these cytokine genes. Our recent
studies indicate that this aspect of mast cell activation is ex-
aggerated in lyn2/2 cells (79), and Btk is required for opti-
mal production of these cytokines (80). Given the Akt
hyperphosphorylation in lyn2/2 cells and the Akt hypo-
phosphorylation in btk2/2 cells, we examined whether Akt
activity is involved in cytokine gene expression. To this
end, we cotransfected BMMCs with wt or DN Akt cDNA
expression vectors together with IL-2/luc or TNF-a/luc
reporter plasmids (Fig. 3). Overexpression of wt Akt en-
hanced twofold induction of IL-2 promoter–driven lu-
ciferase expression over the vector-transfected cells upon
FceRI cross-linking. FceRI-induced transcriptional activa-
tion was almost abrogated by two different DN Akt mu-
tants. Similar results were obtained with TNF-a/luc.
Given these results, together with higher transcriptional
activity of IL-2 and TNF-a promoters (Figure 8 in refer-
ence 79) and higher production of these cytokines (Figure
7 in reference 79) in lyn2/2 mast cells compared with wt
Figure 2. PTK dependence on Akt activation induced by FceRI cross-
linking. (A) BMMCs derived from wt, lyn2/2, and btk2/2lyn2/2 mice
were sensitized by IgE and stimulated with antigen for the indicated
amounts of time. Cells were analyzed for Akt Ser-473 phosphorylation
and Akt amounts. Stim., stimulation. (B) wt and btk2/2 BMMCs and (C)
Syk-deficient (syk2) and Syk-reconstituted (syk1) Syk-deficient RBL-
2H3 cells were similarly analyzed. Similar results shown in A–C were re-
produced in two more independent experiments. Stim., stimulation.
Figure 3. Akt regulation of IL-2 and TNF-a promoter activities. wt
BMMCs were transfected with IL-2/luc or TNF-a/luc reporter plasmids
together with an empty vector or a vector coding for wt, K179M, or
AAA Akt. 24 h later, cells were sensitized with IgE overnight. Cells were
then stimulated with antigen for the last 8 h before luciferase assays. The
IL-2/luc results are representative of three transfection experiments, and
the TNF-a/luc results are representative of two experiments. Stim.,
stimulation.733 Kitaura et al.
cells, higher cytokine production in FceRI-stimulated
lyn2/2 cells may be accounted for at least partly by the
higher activation levels of Akt via the transcriptional regu-
lation. Indeed, overexpression of wt Akt in lyn2/2 cells en-
hanced the transcriptional activity of IL-2 and TNF-a pro-
moters more than that in wt cells, and DN Akt inhibited it
(data not shown).
Transcription Factor NF-kB Is under the Control of Akt.
Expression of IL-2 and TNF-a genes requires several tran-
scription factors, including NF-kB, AP-1, and NF-AT
(65). Therefore, we examined whether the activity of these
transcription factors is regulated by Akt in mast cells. First,
the luciferase gene under the control of multiple copies of
the NF-kB site (2206 to 2202, eight times) of the murine
IL-2 promoter was cotransfected into BMMCs with wt,
E40K, or DN Akt (Fig. 4 A). wt Akt transfection doubled
NF-kB–dependent transcription before stimulation, whereas
FceRI stimulation did not enhance it any further. Consti-
tutively active E40K mutant transfectants exhibited a fur-
ther enhancement in basal and induced levels of NF-kB ac-
tivity. Importantly, these activities were strongly inhibited
by DN Akt. Because of the possible general negative effect
of DN Akt expression, we evaluated whether DN Akt in-
duces apoptosis in BMMCs. Because the efficiency of tran-
sient transfection used in the above experiments was too
low (,20%), to address this issue, we made stable transfec-
tants using wt or DN Akt retroviral constructs. Puromycin-
resistant transfectants were stained with annexin V (to de-
tect early apoptotic cells) and propidium iodide (to detect
late apoptotic or dead cells), followed by FACS® analysis.
The results indicated no enhanced apoptosis in DN Akt–
transfected cells (data not shown; see Fig. 6 A for Akt ex-
pression). Therefore, these results indicate that Akt posi-
tively regulates the NF-kB activity.
IkB regulates NF-kB by sequestering NF-kB in the cy-
toplasm, and phosphorylation by IKK and subsequent deg-
radation of IkB releases this inhibition (60). Therefore, we
examined whether DN IkB-a (IkBaM) and DN IKKa
(K44M) affect NF-kB/luc reporter activity. As shown in
Fig. 4 B, transcriptional activation of NF-kB was strongly
inhibited by DN IkB-a or DN IKKa. In keeping with
these results and the enhanced Akt phosphorylation in
lyn2/2 cells, phosphorylation of Ser-32 in IkB-a (by IKK)
was severalfold higher in FceRI-stimulated  lyn2/2 mast
cells than that in wt cells (Fig. 4 C). These data are also
consistent with a recent study that demonstrated that Akt
can directly phosphorylate IKKa at Ser-32 (81).
Transcription Factors NF-AT and AP-1 Are also Regulated
by Akt. Luciferase constructs driven by multiple copies of
other cis-elements of the IL-2 promoter, i.e., NF-AT
(2290 to 2261, seven times) and AP-1 (65), were also
tested by cotransfection with wt or DN Akt (Fig. 5, A and
B). NF-AT/luc activity was significantly enhanced in
FceRI-stimulated, wt Akt–transfected cells compared with
FceRI-stimulated, vector-transfected cells. Importantly,
these activities were inhibited by two DN Akt (K179M
and AAA) mutants, indicating a role for Akt in signal trans-
duction leading to activation of this transcription factor in
mast cells. AP-1/luc activity was also affected significantly,
albeit to a lesser extent, by wt or DN Akt expression.
JNK is involved in the regulation of both NF-AT and
AP-1 activities (41, 65). Therefore, effects of Akt on JNK
activity were examined with wt BMMCs stably transfected
with wt or DN Akt (Fig. 5 C). FceRI-induced JNK1 acti-
vation was not significantly affected by wt or DN Akt.
Similar to JNK activity, FceRI-induced ERK activation, as
measured by phosphorylation at the activation-loop Thr-
202 and Tyr-204 residues of ERK1 and ERK2, was barely
affected by wt and DN Akt.
These data suggest that the effect of Akt on NF-AT and
AP-1 activities is not through the regulation of JNK. GSK-3
controls the nuclear export of NF-AT (71). Phosphoryla-
tion at Ser-9 of GSK-3b by Akt inhibits its catalytic activity
and blocks the nuclear export of NF-AT. Therefore, we
Figure 4. Akt regulation of the NF-kB pathway. (A) wt BMMCs were
transfected with an NF-kB/luc reporter plasmid together with an empty
vector or a vector encoding wt, E40K, or K179M Akt. 24 h later, cells
were sensitized with IgE overnight. Cells were then stimulated with anti-
gen for the last 8 h before luciferase assays. Representative results out of
three transfection experiments are shown. (B) wt BMMCs were cotrans-
fected with NF-kB/luc and either an empty vector, DN IkB-a (IkBaM),
or DN IKKa (K44M). Results are representative of two experiments.
Stim., stimulation. (C) wt and lyn2/2 BMMCs were sensitized by IgE and
stimulated with antigen for the indicated amounts of time. Cell lysates
were analyzed by immunoblotting with antiphospho–IkB-a (phosphory-
lated Ser-32) antibody followed by reprobing with anti–IkB-a. Results
are representative of two similar experiments. Stim., stimulation.734 Akt Activation in Mast Cells
compared the phosphorylation status of Ser-9 of GSK-3b
between wt and lyn2/2 BMMCs. As shown in Fig. 5 D,
Ser-9 phosphorylation in GSK-3b was higher at z10–30
min after FceRI stimulation in lyn2/2 cells than in wt
counterparts. A slower mobility of GSK-3a on SDS gels
was observed at z10–30 min in wt cells, and this mobility
shift was more pronounced in lyn2/2 cells than in wt cells.
These data are consistent with the notion that Akt-medi-
ated NF-AT activation in FceRI-stimulated mast cells is
through the phosphorylation and inhibition of GSK-3 by
Akt. To further examine whether GSK-3 is involved in the
regulation of NF-AT activity, wt BMMC was transiently
cotransfected with DN GSK-3b and NF-AT/luc plasmids.
DN GSK-3b expression enhanced the FceRI-induced ac-
tivation of NF-AT–driven transcription (Fig. 5 A). Expres-
sion of DN GSK-3b also enhanced the FceRI-induced ac-
tivation of AP-1–driven transcription (Fig. 5 B). Given the
lack of the effect of Akt on the activity of JNK and ERK,
Akt-mediated AP-1 activation may also be through GSK-3,
as GSK-3 is known to inhibit AP-1 activity by phosphory-
lating Jun (82).
Akt Regulates Cytokine Production in Mast Cells. All the
above data suggest that cytokine production may be regu-
lated by Akt through the regulation of multiple transcrip-
tion factors including NF-kB, NF-AT, and AP-1. To di-
rectly test this possibility, we mused puromycin-resistant,
stable transfectants of wt BMMCs by retroviral infection
with empty vector, HA-tagged wt, or K179M Akt viruses.
Transfected Akt was expressed at approximately two- to
threefold more than the endogenous Akt level (Fig. 6 A).
Akt Ser-473 phosphorylation induced by FceRI stimula-
tion in wt Akt–transfected cells was higher than that in
control vector–transfected cells, whereas it was less pro-
nounced in K179M Akt–transfected cells (Fig. 6 A). More
than 98% of these trasnfected cells were viable in culture
medium containing IL-3 and SCF. Upon FceRI stimula-
tion, wt Akt transfectants secreted more IL-2 and TNF-a
than vector-transfected cells, whereas K179M Akt transfec-
tants secreted less than vector-transfectants (Fig. 6 B). lyn2/2
BMMCs transfected with wt or K179M Akt viruses exhib-
ited similar patterns of IL-2 and TNF-a production (data
not shown). Taken together, these data indicate that Akt
positively regulates IL-2 and TNF-a production and secre-
tion in mast cells.
Discussion
This study indicates that Akt is activated by FceRI stim-
ulation in mast cells. Extracellular stimuli that induce Akt
activation include growth factors, cytokines, and antigen
Figure 5. Akt regulation of NF-AT transcription factor. wt BMMCs were transfected with (A) NF-AT/luc or (B) AP-1/luc reporter plasmids to-
gether with an empty vector or a vector encoding wt Akt, K179M Akt, AAA Akt, or DN GSK-3b. 24 h later, cells were sensitized with IgE overnight.
Cells were then stimulated with antigen for the last 8 h before luciferase assays. Shown are the representative results of two transfection experiments.
Stim., stimulation. (C) wt BMMCs stably transfected with an empty vector, wt Akt or K179M Akt, were IgE sensitized and stimulated with antigen. Cell
lysates were either directly analyzed by SDS-PAGE followed by immunoblotting with anti-phospho-ERK (for ERK assays) or immunoprecipitated with
anti-JNK1 antibody before being subjected to kinase assays using GST-c-Jun as an exogenous substrate (for JNK1 assays). Equal expression of ERK1,
ERK2, JNK1, and JNK2 was confirmed by probing immunoblots of total cell lysates with appropriate antibodies. Stim., stimulation. (D) wt and lyn2/2
BMMCs were stimulated with IgE and antigen. Cell lysates were analyzed by immunoblotting with phosphospecific anti–GSK-3b (pSer9) antibody. The
same blot was then reprobed with anti–GSK-3a/b antibody. Stim., stimulation.735 Kitaura et al.
receptors. Most, if not all, of these stimuli promote cell sur-
vival and proliferation. Indeed, FceRI cross-linking and
stimulation with SCF and IL-3, two major mast cell
growth factors, exhibited these properties, i.e., survival/
proliferation and Akt activation (Fig. 1; reference 83; data
on Akt phosphorylation by IL-3 and SCF not shown). Al-
though mechanisms by which Akt activation contributes to
cell proliferation are not fully understood, some of the
known Akt targets are involved in cell survival. A proapop-
totic member of the Bcl-2 family BAD is phosphorylated at
Ser-136 by Akt (67, 84, 85). The phosphorylated BAD be-
comes sequestered by 14-3-3 proteins and cannot het-
erodimerize with and inhibit the survival activity of the
proteins Bcl-2 or Bcl-XL. However, some cytokine-medi-
ated cell survival and Akt activation are not correlated with
BAD phosphorylation (86–88). Caspase-9, an initiator
caspase of apoptosis, is another target of Akt, and phosphor-
ylation of caspase-9 at Ser-196 by Akt inhibits its protease
activity (89). Another antiapoptotic mechanism by Akt is
phosphorylation of forkhead family transcription factors.
Phosphorylation of multiple sites in FKHRL1, AFX, and
FKHR1 transcription factors results in inhibiting their tran-
scriptional activity (90–92). FKHRL1 phosphorylated by
Akt is bound to 14-3-3 proteins and retained in the cyto-
plasm, and is prevented from activating the gene(s) in-
volved in apoptosis (90). It remains to be explored whether
any of these known antiapoptotic mechanisms contribute
to the mast cell survival/proliferation induced by FceRI
stimulation.
A hallmark of FceRI-induced mast cell activation is the
production and secretion of various cytokines including IL-1,
IL-2, IL-3, IL-4, IL-6, IL-9, IL-13, GM-CSF, TNF-a, etc.
Among this expanding list of cytokines, TNF-a is known
to play a critical role in late phase reactions of hypersensi-
tivity (19). Potential mechanisms for allergic inflammation
may include the antiapoptotic effect of TNF-a on mono-
cytes (93). Production of cytokines such as IL-2 and TNF-a
is regulated at several steps: gene transcription, mRNA sta-
bility, translation, and posttranslational modification. One
of the critical regulatory steps is transcription. As shown for
other cell types, numerous cis-transcriptional elements that
are binding sites for transcription factors are involved in
transcriptional activation of the IL-2 gene in FceRI-stimu-
lated mast cells (65). This study provides evidence that Akt
regulates transcriptional activity of NF-kB, NF-AT, and
AP-1 that is critical for the expression of the IL-2 and
TNF-a genes. Phosphorylation of the inhibitor IkB-a
seems to be under the control of Akt as a signaling inter-
mediary from Akt to NF-kB, because phosphorylation of
IkB-a at Ser-32 (the phosphorylation site by IKK) was en-
hanced in lyn2/2 mast cells in which Akt is hyperactivated.
Because DN IkB-a and DN IKKa inhibit FceRI-induced
NF-kB activity, Akt may phosphorylate and activate IKK,
and IKK in turn phosphorylates and promotes the degrada-
tion of IkB. Then free from IkB, NF-kB can translocate to
the nucleus. During the revision of this manuscript, two
groups showed that Btk regulates NF-kB in B cells (94,
95), in apparent agreement with our results in mast cells. As
several other kinases such as Cot, MEKK1-3, and NF-kB–
inducing kinase were shown to be capable of phosphorylat-
ing IKK, it will be interesting to determine whether Akt
directly phosphorylates IKKa in mast cells, as shown for
TNF- and platelet-derived growth factor (PDGF)-stimu-
lated cells (81, 96).
GSK-3 phosphorylation by Akt may be involved in
NF-AT and AP-1 activation in mast cells. Akt can phos-
phorylate and inhibit GSK-3 (71). Consistent with this es-
tablished fact, phosphorylation of GSK-3b at Ser-9 was en-
hanced in lyn2/2 mast cells, which exhibit hyperactive Akt
upon FceRI stimulation. GSK-3 in turn is known to phos-
phorylate NF-AT and regulate the nuclear exit of this tran-
scription factor. GSK-3 is also known to phosphorylate Jun
proteins to inhibit AP-1 activity (82). Although Akt over-
expression exhibited little effect on ERK and JNK activity,
it significantly affected the activities of NF-AT and AP-1
(Fig. 5). Therefore, Akt-dependent phosphorylation of
GSK-3 may regulate NF-AT and AP-1 without substan-
tially affecting the canonical MAPK activation pathways,
i.e., the Raf-1/MEK/ERK and MEKK/MAPK kinase 4
(or MAPK kinase 7)/JNK pathways.
In summary, we provide the first evidence for the in-
volvement of Akt in FceRI-induced production of IL-2
and TNF-a. Production of these cytokines is critical to late
Figure 6. Akt regulates cytokine secretion in FceRI-stimulated mast
cells. Retroviruses coding for HA-tagged wt or K179M Akt were used to
overexpress Akt proteins in stably transfected wt BMMCs. (A) Expression
of HA-tagged Akt and endogenous Akt proteins was confirmed by im-
munoblot analysis of lysates or immune complexes precipitated with anti-
HA or anti-Akt. Stable transfectants were sensitized with anti-DNP IgE
and stimulated with DNP-HSA for the indicated periods of time. Cell ly-
sates were also analyzed for Akt Ser-473 phosphorylation. Stim., stimula-
tion; vec, vector. (B) Transfectants were sensitized with anti-DNP IgE
and stimulated with the indicated concentrations of DNP-HSA for 20 h.
IL-2 and TNF-a secreted into culture media were measured by ELISA.
Values of secreted cytokines varied ,10% from the averages among trip-
licate samples, and therefore SDs were not shown. Similar results were
observed in another set of transfectants.736 Akt Activation in Mast Cells
phase reactions of IgE-dependent hypersensitivity. Al-
though Akt itself may not be a target for pharmaceutical in-
terference to control allergic reactions and immunological
diseases, our findings of Akt as a novel component of the
signaling pathways leading to cytokine production have
provided new insight into the exquisite networks of signal-
ing molecules for mast cell activation.
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